A Single Institutional Experience Using Romiplostim to Treat Therapy‐Related Thrombocytopenia in Pediatric Solid Tumor Patients

Chemotherapy‐induced thrombocytopenia (CIT) is a common toxicity in patients with cancer, leading to chemotherapy dose reductions and increased platelet transfusions. Although there are well‐documented data using thrombopoietin receptor agonists (TPO‐RA) in both adult CIT and pediatric immune thrombocytopenia, there is a paucity of data in pediatric CIT. This is a single institutional, retrospective study evaluating the use and safety of romiplostim in pediatric patients with solid tumors undergoing cancer treatment. Romiplostim was well tolerated and appeared to provide clinical benefit. This report advocates for further research using TPO‐RA in pediatric patients being treated for cancer.